Close Menu

More articles about Business, Policy & Funding

The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.

On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.

Illumina also said it is developing a regulated version of its high-throughput NovaSeq system to address growing demand for a diagnostic platform with higher throughput.

The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.

Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.

The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.

The deal gives Definitive Healthcare a foothold in the genomics market as it looks to build its own genomic data pipeline to serve through PatientFinder's CohortBuilder tool.

Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.

In December, the companies agreed to develop CRISPR tools with the aim of generating new engineered cell lines for the biopharmaceutical industry.

The Korean company said it plans to use equipment and reagents from Thermo Fisher and to expand its overseas markets for CE sequencing services.

The European firms will collaborate to scale up manufacturing of proprietary silicon chips used in Evonetix's benchtop DNA synthesis platform.

Contextual Genomics' recently launched assay screens for cell-free circulating tumor DNA in plasma to identify somatic genome alterations.

The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.

The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

The company said it anticipates $19.2 million in revenues for full-year 2019, which would miss the consensus Wall Street estimate of $19.4 million.

The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.

Though the firm's top-line figures fell just shy of analysts' estimates, its installed base of ePlex analyzers grew 49 percent year over year.

Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.

Revenues of $850.5 million beat the company's prior revenue guidance, as well as the consensus Wall Street estimate.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.